Abstract
Metastatic breast carcinoma in men is usually responsive to hormonal therapy. Most ablative and additive hormonal therapies reported have had objective response rates in excess of 50%. Anastrozole has excellent antitumor activity in postmenopausal women, but no data exist on its efficacy in men. Medical records for all men with a diagnosis of breast cancer who were treated at M. D. Anderson from 1990 to 1999 were reviewed. Five male patients with metastatic breast cancer who were treated at M. D. Anderson with anastrozole were identified. We now report on these five cases.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Aged, 80 and over
-
Anastrozole
-
Antineoplastic Agents, Hormonal / therapeutic use*
-
Aromatase Inhibitors*
-
Bone Neoplasms / drug therapy
-
Bone Neoplasms / secondary
-
Breast Neoplasms, Male / drug therapy*
-
Breast Neoplasms, Male / pathology*
-
Breast Neoplasms, Male / therapy
-
Combined Modality Therapy
-
Enzyme Inhibitors / therapeutic use*
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / secondary*
-
Lymphatic Metastasis
-
Male
-
Middle Aged
-
Nitriles / therapeutic use*
-
Treatment Failure
-
Triazoles / therapeutic use*
Substances
-
Antineoplastic Agents, Hormonal
-
Aromatase Inhibitors
-
Enzyme Inhibitors
-
Nitriles
-
Triazoles
-
Anastrozole